Systemic Therapy for Metastatic Uveal Melanoma

Eric H. Bernicker

Research output: Chapter in Book/Report/Conference proceedingChapter


Metastatic uveal melanoma (UM) is a notoriously difficult to treat malignancy with limited therapeutic options. While the ability to identify patients at high risk of recurrence based on gene-expression profiling has allowed those patients to undergo more frequent surveillance, the lack of effective adjuvant therapies has not prevented recurrences, and earlier identification of metastases has not translated into higher response rates. Chemotherapy has had very limited efficacy, even when delivered intrahepatically. Immunotherapy and targeted agents, which have revolutionized the care of patients with metastatic cutaneous melanoma, have had limited and disappointing success in UM. This chapter will discuss some of the data on various agents in the treatment of patients with advanced disease, outline some of the resistance mechanisms at play, and outline some possible attractive approaches in the future.

Original languageEnglish (US)
Title of host publicationUveal Melanoma
Subtitle of host publicationBiology and Management
PublisherSpringer International Publishing
Number of pages10
ISBN (Electronic)9783030781170
ISBN (Print)9783030781163
StatePublished - Jan 1 2021


  • Immunotherapy
  • Metastatic uveal melanoma
  • Targeted therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Systemic Therapy for Metastatic Uveal Melanoma'. Together they form a unique fingerprint.

Cite this